Adjuvant abemaciclib‑induced pneumonitis: A case report and review of the literature

Al‑Ghabban,Abdulrahman; Al‑Shibany,Aisha; Al‑Shangiti,Khadija; Aseafan,Mohamed; Latif,Kousay; Al‑Tweigeri,Taher

doi:10.3892/wasj.2021.99

Adjuvant abemaciclib‑induced pneumonitis: A case report and review of the literature

Authors:
- Abdulrahman Al‑Ghabban
- Aisha Al‑Shibany
- Khadija Al‑Shangiti
- Mohamed Aseafan
- Kousay Latif
- Taher Al‑Tweigeri
View Affiliations

Affiliations: Department of Medical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh 11564, Saudi Arabia, Department of Radiology, King Faisal Specialist Hospital and Research Center, Riyadh 11564, Saudi Arabia
Published online on: April 12, 2021 https://doi.org/10.3892/wasj.2021.99
Article Number: 28
Copyright : © Al‑Ghabban et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cyclin‑dependent kinase 4/6 (CDK 4/6) inhibitors have been a major addition to the treatment of hormone receptor‑positive, human epidermal growth factor receptor 2 (HER2)‑negative breast cancer in the metastatic setting and currently in the adjuvant setting with promising results. However, rare yet potentially fatal side‑effects such as interstitial lung disease (ILD)/pneumonitis has been linked to the use of these drugs. The present study describes the case of a female patient with locally advance hormone receptor‑positive, HER2‑negative breast cancer who developed abemaciclib‑induced pneumonitis in the adjuvant setting (monarchE clinical trial). The patient was diagnosed based on presenting with symptoms of cough and shortness of breath, and by a computerized tomography scan after ruling out other causes. The patient exhibited the resolution of her symptoms completely following the discontinuation of abemaciclib treatment.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	National Cancer Institute: SEER Cancer Statistics Review, 1975-2016. https://seer.cancer.gov/archive/csr/1975_2016/. Accessed: June 30, 2020.
3	de Melo Gagliato D, C Buzaid A, Perez-Garcia JM, Llombart A and Cortes J: CDK4/6 Inhibitors in hormone receptor-positive metastatic breast cancer: Current practice and knowledge. Cancers (Basel). 12(2480)2020.PubMed/NCBI View Article : Google Scholar
4	U.S. Food and Drug: FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-initial-therapy-hr-positive-her2-negative-metastatic-breast-cancer. Accessed March 27, 2021.
5	U.S. Food and Drug: FDA apporves palbociclib as a treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women; https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance. Accessed March 27, 2021.
6	U.S. Food and Drug: FDA approved ribociclib, a cyclin-dependent kinase 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer; https://www.fda.gov/drugs/resources-information-approved-drugs/ribociclib-kisqali. Accessed March 27, 2021.
7	European Medicine Agency (EMA): EMA approval of palbociclib; https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance. Accessed March 27, 2021.
8	European Medicine Agency (EMA): EMA approval of ribociclib; https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali. Accessed March 27, 2021.
9	European Medicine Agency (EMA): EMA approval of abemaciclib; https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios. Accessed March 27, 2021.
10	Saudi FDA: Approval and registration of palbociclib; https://sdi.sfda.gov.sa/Home/Result?drugId=7121. Accessed March 28, 2021.
11	Saudi FDA: Approval and registration of ribociclib; https://sdi.sfda.gov.sa/Home/Result?drugId=7956. Accessed March 28, 2021.
12	Saudi FDA: Approval and registration of abemaciclib; https://sdi.sfda.gov.sa/Home/Result?drugId=8132. Accessed March 28, 2021.
13	Piezzo M, Cocco S, Caputo R, Cianniello D, Gioia GD, Lauro VD, Fusco G, Martinelli C, Nuzzo F, Pensabene M and Laurentiis M: Targeting cell cycle in breast cancer: CDK4/6 inhibitors. Int J Mol Sci. 21(6479)2020.PubMed/NCBI View Article : Google Scholar
14	Chen X, Xu D, Li X, Zhang J, Xu W, Hou J, Zhang W and Tang J: Latest overview of the cyclin-dependent kinases 4/6 inhibitors in breast cancer: The past, the present and the future. J Cancer. 10:6608–6617. 2019.PubMed/NCBI View Article : Google Scholar
15	Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, et al: CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: A US food and drug administration pooled analysis. Lancet Oncol. 21:250–260. 2020.PubMed/NCBI View Article : Google Scholar
16	Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, et al: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 29:1541–1547. 2018.PubMed/NCBI View Article : Google Scholar
17	Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, et al: Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. Lancet Oncol. 19:904–915. 2018.PubMed/NCBI View Article : Google Scholar
18	Hurvitz SA, Im SA, Lu YS, Colleoni M, Franke FA, Bardia A, Harbeck N, Chow L, Sohn J, Lee KS, et al: Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2-advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. J Clin Oncol. 37(LBA1008)2019.PubMed/NCBI View Article : Google Scholar
19	Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, et al: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 36:2465–2472. 2018.PubMed/NCBI View Article : Google Scholar
20	Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, et al: Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Ann Oncol. 30:V856–V857. 2019.
21	Slamon DJ, Neven P, Chia SKL, Im SA, Fasching PA, DeLaurentiis M, Petrakova K, Bianchi GV, Esteva FJ, Martin M, et al: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3. J Clin Oncol. 36(1000)2018.
22	Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, et al: Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 382:514–524. 2020.PubMed/NCBI View Article : Google Scholar
23	Lu YS, Bardia A, Vázquez RV, Colleoni MA, Wheatley-Price P, Im YH, Babu G, Tripathy D, Lanoue BR, Chandiwana D, et al: Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial. Ann Oncol. 30(V106)2019.
24	Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, et al: Overall Survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 381:307–316. 2019.
25	Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al: MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer. Ann Oncol. 30(V856)2019.
26	Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al: The Effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. JAMA Oncol. 6:116–124. 2019.PubMed/NCBI View Article : Google Scholar
27	Spring LM, Wander SA, Andre F, Moy B, Turner NC and Bardia A: Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: Past, present, and future. Lancet. 395:817–827. 2020.PubMed/NCBI View Article : Google Scholar
28	Breast cancer drug Verzenio could have serious side effects on lungs Js health ministry warns. The Japan Times. 17 May, 2019.
29	U.S. Food and Drug: FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-severe-lung-inflammation-ibrance-kisqali-and-verzenio-breast-cancer. Accessed September 9, 2019.
30	Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, et al: Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, Node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 38:3987–3998. 2020.PubMed/NCBI View Article : Google Scholar
31	American Heart Association: Classes of Heart Failure; https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure. Accessed March 27, 2021.
32	American Thoracic Society: 2017 ERS/ATS standards for single-breathcarbon monoxide uptake in the lung; https://www.thoracic.org/statements/resources/pft/DLCO.pdf. Accessed March 27, 2021.
33	Omarini C, Thanopoulou E and Johnston SR: Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. Breast Cancer Res Treat. 146:245–258. 2014.PubMed/NCBI View Article : Google Scholar
34	Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al: Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 375:1925–1936. 2016.PubMed/NCBI View Article : Google Scholar
35	Ahsan I, Malik F and Jafri SI: Palbociclib related pnemotoxicity: A rare side effect. In: C43. Drug Induced Lung Disease: Case Reports, ppA5546, 2017.
36	Azhar A, Zaman K and Samad R: A tale of unexplained pneumotoxicity: The dangers of palbociclib. In: B36. Case Reports in Biologic and Chemotherapeutic Agent Induced Lung Disease, ppA3120, 2020.
37	Felip E, Llobera L, Perez-Mañá C, Quintela D, Guasch I, Margelí M, Teruel I, Cirauqui B, Centeno C, Romeo M, et al: New drugs, old toxicities: Pneumonitis related to palbociclib-a case report. Breast Care. 15:548–552. 2020.PubMed/NCBI View Article : Google Scholar
38	Gong J, Cho M, Yu KW, Waisman J, Yuan Y and Mortimer J: A single institution experience with palbociclib toxicity requiring dose modifications. Breast Cancer Res Treat. 168:381–387. 2018.PubMed/NCBI View Article : Google Scholar
39	Jazieh KA, Budd GT, Dalpiaz N and Abraham J: Can CDK4/6 inhibitors cause fatal lung injury? Expert Rev Anticancer Ther. 19:917–919. 2019.PubMed/NCBI View Article : Google Scholar
40	Levy O, Ptashkin E, Shechtman Y, Kas T, Natif N, Sanset S and Katz D: Fatal palbociclib-related interstitial pneumonitis. Arch Clin Med Case Rep. 3:162–166. 2019.
41	Okura F, Sato Y, Murakami E, Komatsu H, Yamamura Y and Ito Y: A case of interstitial pneumonitis induced by palbociclib. Gan To Kagaku Ryoho. 47:997–999. 2020.PubMed/NCBI(In Japanese).
42	Sarkisian S, Markosian C, Ali Z and Rizvi M: Palbociclib-induced pneumonitis: A case report and review of the literature. Cureus. 12:e8929. 2020.PubMed/NCBI View Article : Google Scholar
43	Algwaiz G, Badran AA, Elshenawy MA and Al-Tweigeri T: Ribociclib-induced pneumonitis: A case report. Breast Care: https://doi.org/10.1159/000507647.
44	Liu A: Lilly oncology suffers another blow as Verzenio slapped with safety warning in Japan. Fierce Pharma, 2019. https://www.fiercepharma.com/pharma/lilly-oncology-suffers-another-blow-as-verzenio-slapped-safety-warning-japan. Accessed May 21, 2019.
45	Eli Lilly and Company: Abemaciclib (Verzenio R) US prescribing information. http://pi.lilly.com/us/verzenio-uspi.pdf. Accessed September 2019.
46	Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J and Goetz M: Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 26:e522. 2021.PubMed/NCBI View Article : Google Scholar
47	Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA and Giles FJ: Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 9:207–213. 2017.PubMed/NCBI View Article : Google Scholar
48	Kawajiri H, Takashima T, Onoda N, Kashiwagi S, Ishikawa T and Hirakawa K: Interstitial pneumonia associated with neoadjuvant chemotherapy in breast cancer. Mol Clin Oncol. 1:433–436. 2013.PubMed/NCBI View Article : Google Scholar
49	Bielopolski D, Evron E, Moreh-Rahav O, Landes M, Stemmer SM and Salamon F: Paclitaxel-induced pneumonitis in patients with breast cancer: Case series and review of the literature. J Chemother. 29:113–117. 2017.PubMed/NCBI View Article : Google Scholar